Effectiveness of bone marrow-derived mononuclear stem cells for neurological recovery in participants with spinal cord injury: A randomized controlled trial
- PMID: 31896919
- PMCID: PMC6910030
- DOI: 10.4103/ajts.AJTS_44_18
Effectiveness of bone marrow-derived mononuclear stem cells for neurological recovery in participants with spinal cord injury: A randomized controlled trial
Abstract
Background: Complete lesion after spinal cord injury (SCI) remains irreversible with little hope of neurological recovery. Newer interventions such as re-stimulation of damaged neurons using artificial agents and the use of stem cells for neuronal regeneration have shown promising results.
Aim: This study was undertaken for evaluating the neurological status of acute SCI participants after stem cell augmentation and comparing them with other treatment methods.
Setting and design: Randomized controlled trial in the northern Indian population.
Materials and methods: A total 193 SCI participants of complete paraplegia with unstable T4-L2 injury having thoracolumbar injury severity score ≥4 were enrolled in this study. Participants were randomly allocated for three different treatment modalities, namely, conventional with stem cell augmentation (Group-1), conventional (Group-2), and conservative (Group-3). Neurological recovery after 1 year was evaluated through the ASIA Impairment Scale (AIS)-grading, sensory, and motor scores.
Statistical analysis: T-test for sensory-motor score analysis of each group and analysis of variance for comparison of same variables between the groups.
Results: After 1-year significant difference was observed in the AIS-grade, sensory and motor scores in-Group 1 (P < 0.001). In Group-1 versus 2, the mean difference at 1 year for AIS grade, sensory and motor scores were 0.40 (P = 0.010, 95% confidence interval [CI] 0.075-0.727), 8.52 (P = 0.030, 95% CI 0.619-16.419), and 4.55(P = 0.003, 95% CI 1.282-7.815), respectively. In Group-1 versus 3, 1.03, 19.02 and 7.22 (P < 0.001 for each of the parameters) and in Group-2 versus 3, 0.63 (P < 0.001), 10.49 (P = 0.009), and 2.68 (P = 0.019), respectively.
Conclusions: Significant motor neurological recovery and AIS-grade promotion was observed in Group-1 as compared to Group-2 and 3.
Keywords: Acute spinal cord injury; autologous bone marrow mononuclear stem cells; conventional treatment; neurological recovery; thoracolumbar injury severity score.
Copyright: © 2019 Asian Journal of Transfusion Science.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double-blind randomized controlled clinical trial.J Neurosurg Spine. 2018 Jul;29(1):97-107. doi: 10.3171/2017.11.SPINE17769. Epub 2018 Apr 27. J Neurosurg Spine. 2018. PMID: 29701561 Clinical Trial.
-
Sequential neurological improvements after conservative treatment in patients with complete motor paralysis caused by cervical spinal cord injury without bone and disc injury.J Neurosurg Spine. 2018 Jul;29(1):1-9. doi: 10.3171/2017.10.SPINE17844. Epub 2018 Apr 20. J Neurosurg Spine. 2018. PMID: 29676669
-
Against the odds: what to expect in rehabilitation of chronic spinal cord injury with a neurologically controlled Hybrid Assistive Limb exoskeleton. A subgroup analysis of 55 patients according to age and lesion level.Neurosurg Focus. 2017 May;42(5):E15. doi: 10.3171/2017.2.FOCUS171. Neurosurg Focus. 2017. PMID: 28463613
-
Recovery and regeneration after spinal cord injury: a review and summary of recent literature.Ann Acad Med Singap. 2007 Jan;36(1):49-57. Ann Acad Med Singap. 2007. PMID: 17285186 Review.
-
Stem Cell Therapy for Spinal Cord Injury: A Review of Recent Clinical Trials.Cureus. 2022 Apr 28;14(4):e24575. doi: 10.7759/cureus.24575. eCollection 2022 Apr. Cureus. 2022. PMID: 35664388 Free PMC article. Review.
Cited by
-
Clinical translation of stem cell therapy for spinal cord injury still premature: results from a single-arm meta-analysis based on 62 clinical trials.BMC Med. 2022 Sep 5;20(1):284. doi: 10.1186/s12916-022-02482-2. BMC Med. 2022. PMID: 36058903 Free PMC article.
-
Treatment of rats with spinal cord injury using human bone marrow-derived stromal cells prepared by negative selection.J Biomed Sci. 2020 Feb 18;27(1):35. doi: 10.1186/s12929-020-00629-y. J Biomed Sci. 2020. PMID: 32066435 Free PMC article.
-
Current status and future perspectives on stem cell transplantation for spinal cord injury.World J Transplant. 2024 Mar 18;14(1):89674. doi: 10.5500/wjt.v14.i1.89674. World J Transplant. 2024. PMID: 38576751 Free PMC article.
References
-
- Wirasinghe V, Grover S, Ma D, Vizcaychipi M. Anaesthetic management of patients with acute spinal injury. Internet J Anesthesiol. 2010;30:1–10.
-
- Lukovic D, Stojkovic M, Moreno-Manzano V, Jendelova P, Sykova E, Bhattacharya SS, et al. Concise review: Reactive astrocytes and stem cells in spinal cord injury: Good guys or bad guys? Stem Cells. 2015;33:1036–41. - PubMed
-
- Singh N, Gopal SC, Srivastava RN, Chandra T, Agarwal SP, Singh SK. In vitro maintenance of olfactory mucosa with enriched olfactory ensheathing cells. J Stem Cell Res Ther. 2013;2:132.
LinkOut - more resources
Full Text Sources